Related by context. All words. (Click for frequent words.) 86 randomized placebo controlled 83 randomized double 82 double blind placebo 81 randomized controlled 79 blind randomized placebo 78 multicenter 78 blind randomized 77 randomized 76 prospective randomized 76 randomized clinical 75 blind placebo controlled 75 multicenter randomized 75 multicentre 74 placebo controlled randomized 74 randomized multicenter 74 placebo controlled Phase 73 multicenter randomized double 72 multicenter randomized placebo controlled 72 prospective randomized controlled 71 placebo controlled clinical 71 dose escalation study 71 randomized controlled trial 71 Phase III randomized 71 placebo controlled studies 70 dose escalation trial 70 multicenter placebo controlled 69 randomized Phase III 69 dose escalation 69 double blinded randomized 69 blinded placebo controlled 69 masked placebo controlled 69 single ascending dose 68 Phase 2a clinical 68 placebo controlled trials 68 randomized controlled clinical 68 active comparator 68 controlled multicenter 68 Phase 2b study 68 Phase Ib 68 Phase IIb trial 68 Phase III clinical 68 placebo controlled Phase III 68 multicentre randomized 68 multicentre randomized double 68 Phase IIa 68 Phase 1b clinical 67 nonrandomized 67 tolerability 67 Phase 2b trial 67 Phase 2b clinical 67 label dose escalation 67 Phase 2a trial 67 phase IIa 66 dose escalation Phase 66 Phase IIb 66 Phase 1b 66 label multicenter 66 multicenter study 66 double blinded placebo 66 dose dose escalation 66 prospective randomized placebo 66 clinical trial 66 phase IIb 66 ascending dose 66 blinded randomized 66 blind randomized controlled 66 phase IIb clinical 65 phase IIa clinical 65 Phase Ia 65 prospective multicenter 65 Phase IIIb 65 TMC# C# 65 randomized clinical trials 65 blind multicenter 65 multiple ascending dose 65 Phase IIa clinical 65 Phase IIb clinical 65 randomized controlled clinical trials 65 Phase 2a 65 Phase III 65 multicenter prospective 65 Phase Ib clinical 65 blind placebo 64 Phase 2b 64 multicenter Phase II 64 pivotal Phase III 64 Phase IIa trial 64 observational study 64 blinded randomized placebo controlled 64 multicenter randomized controlled 64 subanalysis 64 AIR CF1 64 Phase 1b trial 64 pharmacokinetics PK 64 viral kinetic 64 Phase III placebo controlled 64 phase IIIb 64 prospective cohort 64 prospective randomized multicenter 64 prospective observational 64 pharmacodynamics 63 phase Ib 63 randomized trials 63 phase 2a 63 safety tolerability pharmacokinetics 63 PRECiSE 63 randomized controlled trials 63 HCV SPRINT 63 randomized Phase 63 mg dose 63 dose titration 63 randomized multicentre 63 multicenter Phase III 63 pivotal Phase 63 randomized multicenter trial 63 Phase #/#a 63 label dose titration 62 ascending doses 62 multicenter clinical 62 safety tolerability 62 dose escalation clinical 62 Phase 1a 62 ADVANCE PD 62 Randomized 62 unblinded 62 placebo controlled clinical trials 62 multicenter Phase 62 pharmacokinetics 62 randomized blinded 62 prospective multicenter randomized 62 multicenter multinational 62 landmark ATHENA 61 TG MV 61 Phase IIIb clinical 61 dosing regimens 61 oral rivaroxaban 61 dose regimens 61 pharmacokinetic 61 multicenter phase 61 VICTOR E1 61 AIR CF2 61 non inferiority 61 mg BID 61 label multicenter randomized 61 Sorafenib HCC Assessment 61 lacosamide 61 desvenlafaxine succinate 61 telaprevir dosing 61 dyskinesia PD LID 61 ONTARGET 61 dose cohorts 60 label multicenter Phase 60 primary endpoint 60 nab paclitaxel 60 controlled dose escalation 60 randomized #:# 60 confirmatory Phase III 60 TAXUS ATLAS 60 Placebo controlled 60 RE LY ® 60 peginterferon alfa 2b 60 multicentre study 60 dosing cohorts 60 placebo controlled dose escalation 60 Phase III pivotal 60 HCV RESPOND 2 60 Phase IIB 60 AIR CF3 60 Randomised 60 analgesic efficacy 60 Phase Ib II 60 prospective nonrandomized 60 symptomatic BPH 59 substudy 59 LUX Lung 59 RRMS patients 59 Phase IIIb study 59 RE LY 59 Phase 2b randomized 59 BRIM2 59 Multicenter 59 prucalopride 59 CIMZIA TM certolizumab pegol 59 LEXIVA r 59 mg QD 59 placebo 59 randomized Phase IIb 59 Phase III clinical trials 59 Phase III trials 59 NO# [002] 59 Traficet EN 59 APTIVUS 59 phase Ib clinical 59 blind multicentre 59 dose placebo controlled 59 tolvaptan 59 GAMMAGARD 59 trials RCTs 59 pharmacokinetic studies 59 observer blinded randomized 59 Phase II 59 #mg/day [001] 59 randomized #:#:# 59 DAPT 59 bosentan 59 efficacy 59 Parkinson disease levodopa induced 59 posaconazole 59 adalimumab 59 riociguat 58 CLARITY study 58 vicriviroc 58 ROCKET AF 58 tiotropium 58 observational studies 58 APTIVUS r 58 CLL8 58 mg administered orally 58 pharmacodynamics PD 58 BOLDER II 58 investigational oral 58 teriflunomide 58 Betaferon ® 58 noninferiority 58 randomized controlled Phase 58 BRIM3 58 safety tolerability pharmacokinetic 58 phase IIb trial 58 relapsing remitting multiple sclerosis 58 PREZISTA r 58 FAME Study 58 dosing cohort 58 Phase Ib study 58 insulin detemir 58 Clinical Antipsychotic Trials 58 ACTIVE W 58 dosage regimens 58 PRE SURGE 58 clinical pharmacology studies 58 administered subcutaneously 58 ACTEMRA 58 FOSRENOL R 58 lubiprostone 58 icatibant 58 meta analysis 58 TAXUS VI 58 treatment naïve genotype 58 pharmacokinetic PK 58 Phase 1a clinical 58 citalopram 58 blind randomized multicenter 58 RG# ITMN 58 MEND CABG 58 RSD# oral 58 prospectively randomized 58 randomized controlled multicenter 58 pharmacodynamic profile 58 primary efficacy endpoint 57 ascending dose study 57 randomized crossover 57 monotherapy 57 AZILECT R 57 COMFORT II 57 interferon beta 1b 57 blinded placebo 57 DURATION 57 CAMMS# 57 Tolvaptan 57 multicenter randomized clinical 57 evaluable patients 57 SPIRIT III 57 EDEMA3 57 fostamatinib 57 ADAGIO study 57 tolerability profile 57 treatment naive genotype 57 pharmacodynamic 57 glatiramer acetate 57 SPIRIT IV 57 pharmacokinetic PK study 57 PRX # 57 pharmacokinetic profile 57 Randomized Phase 57 Carotid Revascularization Endarterectomy vs. 57 ancrod 57 tapentadol ER 57 CYPHER R Sirolimus eluting 57 dosing 57 Efficacy 57 phase IIb study 57 plus ribavirin 57 diabetic neuropathic pain 57 Intervention Effectiveness 57 etanercept 57 primary hypercholesterolemia 57 EURIDIS 57 subgroup analyzes 57 zonisamide SR 57 ibandronate 57 HPTN 57 dose regimen 57 GOUT 57 tolerated dose MTD 57 EQUIP OB 57 Initiated Phase 57 ExTRACT TIMI 57 darunavir ritonavir 57 Phase #b/#a 57 rotigotine 57 pomalidomide 57 LEVADEX 56 demonstrated statistically significant 56 COPAXONE R 56 intravenous dosing 56 subcutaneously administered 56 ACTEMRA TM 56 post hoc 56 prospectively defined 56 NATRECOR ® 56 DLTs 56 solifenacin 56 sunitinib malate 56 oral deforolimus 56 ENDEAVOR IV 56 APEX PD 56 TRANSFORMS 56 STRIDE PD 56 pivotal bioequivalence 56 forodesine 56 IIa trial 56 sirolimus eluting stent 56 thorough QT 56 #mg QD [002] 56 timepoint 56 ABC/3TC 56 Pivotal Trial 56 placebo controlled multicenter 56 Val HeFT 56 dabigatran etexilate 56 interferon gamma 1b 56 afatinib 56 MERLIN TIMI 56 LITHE 56 #mg BID [001] 56 mcg kg 56 ORENCIA ® 56 Phase III randomized controlled 56 #mg dose [003] 56 Phase Ib clinical trials 56 RezularTM 56 abatacept 56 tocilizumab 56 subcutaneous SC 56 IBS C 56 Ophena TM 56 SCH # 56 peginterferon alfa 2a 56 TDF FTC 56 HCV infected 56 Randomized controlled 56 prospective multicentre 56 ANCHOR trial 56 composite endpoint 56 ORMD 56 mg doses 56 RoACTEMRA 56 DSMB 56 dosing regimen 56 Randomized Evaluation 56 laquinimod 56 AIM HIGH 56 PRECISE 56 #mg dose [001] 56 recurrent malignant glioma 56 randomized blinded placebo 56 secondary endpoint 56 ILLUMINATE 56 Laquinimod 56 LibiGel Phase III 56 LCP AtorFen 56 Multiple Ascending Dose 56 randomized multicenter Phase III 56 irbesartan 56 lanthanum carbonate 56 CATIE AD 56 PRoFESS 56 clinical trials 56 dose cohort 56 multicentre randomized controlled 56 PD LID 55 sequential dose escalation 55 pharmacodynamic effects 55 investigational compound 55 ISIS # 55 opioid induced bowel dysfunction 55 dose escalation phase 55 JAK inhibitor 55 secondary efficacy endpoints 55 relapsing multiple sclerosis 55 blinded randomized controlled 55 IFN alfa 55 Phenoptin 55 TEAEs 55 n = 55 investigational drug 55 coadministration 55 pegylated interferon alfa 2b 55 Phase 2b kidney transplant 55 ABSORB trial 55 relapsed myeloma 55 CRx 55 pramlintide 55 tgAAC# 55 KRN# 55 bupropion SR 55 adjunctive placebo 55 subcutaneous dose 55 MIVI III 55 relapsed MM 55 eculizumab 55 ENDEAVOR II 55 Amrubicin 55 Phase 1b dose escalation 55 pramipexole 55 TAXUS V 55 Intervention Trial GAIT 55 rosuvastatin 55 patients evaluable 55 BoNTA 55 AVOREN 55 efficacy endpoints 55 ISENTRESS 55 pharmacodynamic PD 55 ritonavir boosted 55 TMC# [001] 55 salmeterol fluticasone 55 Phase III multicenter 55 GetGoal Phase III 55 ATACAND 55 controlled multicenter Phase 55 LIALDA 55 INCB# [001] 55 colesevelam HCl 55 alvimopan 55 CIMZIA TM 55 headache nasopharyngitis 55 bolus injection 55 RECORD1 55 Dacogen injection 55 mg RDEA# 55 RE SURGE 55 ASTEROID 55 ToGA 55 prespecified 55 EchoCRT 55 null responder HCV 55 rasagiline 55 pegylated interferon 55 REYATAZ r 55 FOSRENOL ® 55 CANCIDAS 55 DU #b 55 secondary endpoints 55 CHAMPION PCI 55 Phase III confirmatory 55 EVIZON 55 Protelos 55 Sym# 55 OPT CHF 55 EVEREST II 55 atazanavir ritonavir 55 AIR2 Trial 55 fluticasone furoate 55 eszopiclone 55 NGX# 55 recurrent glioblastoma multiforme 55 ASCEND HF 55 REALITY Trial 55 ECASS 55 tasocitinib 55 efavirenz EFV 55 AEGR 55 lomitapide 55 retrospective observational study 55 nitazoxanide 55 sorafenib Nexavar 55 venlafaxine XR 55 KAPIDEX 55 LPV r 55 sunitinib 55 multicenter trials 55 Adalimumab 55 intravitreal injection 55 bicifadine 55 MIRCERA 55 mcg dose 55 cilostazol 55 certolizumab pegol 55 confirmatory clinical 55 NLX P# 55 antiretroviral naive 55 tolerability pharmacokinetics 55 NSABP B 55 melphalan prednisone 55 events AEs 55 ARIXTRA 55 INSPIRE Trial Phase III 55 NP2 Enkephalin 55 infliximab 55 CombAT 55 DASISION 55 REVLIMID lenalidomide 55 QD dosing 55 daily Infergen 55 comparator arm 55 Phase IIb trials 55 II Clinical Trial 55 mg kg dose 55 RLAI 55 FOLFOX 55 8mg/kg 54 dose limiting toxicities 54 Neovascular AMD 54 de novo kidney transplant 54 iniparib 54 visilizumab 54 ARCOXIA 54 IDX# 54 ceftazidime 54 recurrent GBM 54 VA# [002] 54 primary endpoints 54 Androxal TM 54 ADMIRE HF 54 virologic response 54 RESOLUTE 54 antiviral activity 54 Phase 54 rFVIIa 54 temsirolimus 54 PreCISe 54 randomized Phase 2b 54 evaluating REVLIMID 54 ziprasidone 54 Prostate Lung Colorectal 54 APPRAISE 54 evaluating tivozanib 54 IMPROVE IT 54 Phase IIa trials 54 weekly subcutaneous injections 54 brivaracetam 54 MADIT II 54 Empatic 54 registrational 54 telmisartan 54 SPIRIT FIRST 54 tanespimycin 54 achieved statistical significance 54 6R BH4 54 phase IIb III 54 GSK# [001] 54 NOXAFIL Oral Suspension 54 Edge STudy 54 aflibercept 54 palonosetron 54 oral diclofenac 54 phase III ACCLAIM 54 pharmacokinetic pharmacodynamic 54 events SAEs 54 NRTI 54 Placebo Controlled 54 pegylated interferon alfa 2a 54 eltrombopag 54 CIMZIA R 54 Betaferon R 54 cetrorelix 54 mg TID 54 PRTX 54 intra articular injection 54 acute HAE attacks 54 HOPE TOO 54 risperidone Risperdal 54 elagolix 54 oxycodone CR 54 beta2 agonist 54 RG# [001] 54 teriparatide 54 RIO Lipids 54 Microplasmin 54 denufosol 54 Dose escalation 54 OLYMPIA registry 54 SYMBICORT 54 C1 INH 54 oral prodrug 54 Navelbine 54 FOLFIRI 54 relapsing remitting MS 54 QLT# 54 fluvastatin 54 duloxetine 54 retrospective cohort study 54 VADT 54 superficial bladder cancer 54 RE LY trial 54 CTA# Injection 54 SEROQUEL 54 eosinophilic asthma 54 PreCISe study 54 olanzapine 54 Phase 2b clinical trials 54 Myocardial Infarction Study 54 BARI 2D 54 mycophenolate mofetil 54 confirmatory Phase 3 54 oral ridaforolimus 54 Randomized Double Blind Placebo 54 Controlled Trial 54 AGILECT R 54 relapsing remitting MS RRMS 54 orally administered 54 bepotastine besilate nasal spray 54 intermittent dosing 54 CIMZIA ™ 54 comparing XIENCE V 54 bendamustine 54 Phase IIb III 54 Sibutramine Cardiovascular Outcomes 54 efalizumab 54 viral kinetics 54 candesartan cilexetil 54 peg IFN 54 Randomized Double blind 54 pitavastatin 54 mg/m2 dose 54 ataluren 54 HZT 54 tacrolimus ointment 54 multicentre prospective 54 CYPHER ® Sirolimus eluting 54 postmenopausal osteoporotic women 54 efficacy endpoint 54 μg dose 54 multinational multicenter randomized 54 randomized placebo 54 intravenously administered 54 safinamide 54 valsartan 54 aripiprazole 54 mcg doses 54 aripiprazole Abilify 54 PFO migraine 54 bevacizumab 54 Dapagliflozin 54 Pegasys plus Copegus 54 PRIMO CABG 54 ritonavir boosted atazanavir 54 levetiracetam 54 ADX# 53 TRITON TIMI 53 urate lowering 53 migraine prophylaxis 53 Zenvia ™ 53 Prostate Cancer Prevention 53 elotuzumab 53 pharmacokinetic parameters 53 MoxDuo TM IR 53 Arikace 53 Zerenex 53 ARDIS 53 NCCTG 53 mcg BID 53 FTY# fingolimod 53 pegylated liposomal doxorubicin 53 rapid virologic response 53 Secondary endpoints 53 registrational Phase 53 NXL# 53 NEVO RES 53 MAGE A3 ASCI 53 ongoing Phase 1b 53 oral FTY# 53 Communities ARIC study 53 hour bronchodilation 53 liver transplant recipients 53 dimebon 53 Prospective Randomized 53 CRESTOR #mg 53 #mg/m# [002] 53 Plicera 53 factorial design 53 TAXUS IV 53 JANUVIA 53 atypical antipsychotic 53 telcagepant 53 alicaforsen enema 53 Phase IIA 53 treatment emergent adverse 53 Phase III Clinical Trial 53 tipranavir 53 standard chemotherapy regimen 53 BCIRG 53 carboplatin paclitaxel 53 BOLDER 53 AZILECT 53 acute PAO 53 AVADO 53 MIST II 53 Safinamide 53 SPARCL 53 RSD# 53 goserelin 53 evaluating Xcytrin 53 #mg QD [001] 53 Prostate AdenoCarcinoma Treatment 53 metastatic HRPC 53 NOXAFIL 53 Monotherapy 53 low dose cytarabine 53 ENDEAVOR clinical 53 mcg albinterferon alfa 2b 53 mGluR5 NAM 53 chlorambucil 53 dirucotide MBP# 53 VIRAMUNE XR 53 pharmacokinetic characteristics 53 multidose 53 fenofibric acid 53 RAPAFLO R 53 ABSORB clinical 53 Tyrima 53 EINSTEIN DVT 53 sulodexide 53 PROPEL trial 53 Polyp Prevention Trial 53 rt PA 53 #:# randomization 53 MIRAPEX 53 axitinib 53 strontium ranelate 53 Cloretazine R VNP#M 53 HORIZONS AMI 53 postmenopausal women 53 maximally tolerated dose 53 Multi Ethnic Study 53 IIa clinical trial 53 lixisenatide 53 GFT# 53 #mg BID [003] 53 quetiapine 53 desvenlafaxine 53 multicenter randomized Phase 53 Phase #b/#a trial 53 ticagrelor 53 #mg/day [002] 53 albinterferon alfa 2b 53 evaluable subjects 53 candesartan 53 ENESTnd 53 odanacatib 53 dacarbazine 53 pregabalin 53 eptifibatide 53 galiximab 53 iPrEx 53 4mg/kg 53 citalopram hydrobromide 53 CARE HF 53 CUSTOM II 53 DDP# 53 VFEND 53 divalproex sodium 53 docetaxel 53 cannabinor 53 Cimzia ® certolizumab pegol 53 Denufosol 53 atorvastatin Lipitor 53 Teriflunomide 53 metreleptin 53 #mg [003] 53 CERVARIX 53 Diamyd ® 53 Phase III randomized placebo 53 EQUATE OB 53 pioglitazone 53 inhalations twice 53 dosing schedules 53 retrospective cohort 53 rALLy clinical trial 53 EFAPROXYN 53 Pivotal Phase 53 Pharmacokinetics PK 53 canakinumab 53 allopurinol 53 label titration 53 efficacy tolerability 53 DPNP 53 q8h 53 sitagliptin 53 BR.# 53 secondary efficacy endpoint 53 octreotide LAR 53 stage IIIB 53 temozolomide 53 methylnaltrexone 53 tarenflurbil 53 biologic therapy 53 FREEDOMS 53 CYPHER R Stent 53 REYATAZ ritonavir 53 eprotirome 53 unblinding 53 doxorubicin cyclophosphamide 53 dose pharmacokinetic 53 LUMINATE 53 Acute Ischemic Stroke 53 mitoxantrone 53 trastuzumab emtansine T DM1 53 adult chronic ITP 53 Taxotere ® 53 Taxotere R 53 huC# DM4 53 pharmacokinetics pharmacodynamics 53 meta analyzes 53 perampanel 53 Perforomist Inhalation Solution 53 dosed 53 inhaled corticosteroid ICS 53 glycopyrrolate 53 PSN# [002] 53 Pegasys ® 53 daunorubicin 53 ribavirin RBV 53 Rosuvastatin 53 edoxaban 53 REVIVE Diabetes 53 azacitidine 53 cediranib 53 telaprevir dosed 53 dosing intervals 53 Initiate Phase 53 PF # [001] 53 olmesartan 53 SCIg 53 relapsed refractory multiple myeloma 53 cathepsin K inhibitor 53 prospective observational cohort 53 pyridostigmine 53 peginterferon 53 hemodialysis patients 53 ONGLYZA 53 PEGylated interferon beta 1a 53 serotonin norepinephrine reuptake inhibitor 53 oral olanzapine 53 refractory CLL 53 HuMax EGFr 52 donepezil 52 BENICAR HCT 52 muraglitazar 52 timepoints 52 dexpramipexole 52 dosed orally 52 dexamethasone Decadron 52 protease inhibitor PI 52 EOquin TM 52 Tiotropium 52 FASLODEX 52 Phase III psoriasis 52 registrational trial 52 PPAR gamma agonist 52 olanzapine Zyprexa 52 evaluable 52 abacavir lamivudine 52 docetaxel chemotherapy 52 tenofovir emtricitabine 52 mirtazapine 52 TMC# r 52 Proellex TM 52 Study ADX# 52 chemoradiotherapy 52 virologic failure 52 Tarceva TM 52 metastatic hormone refractory 52 CUSTOM III 52 rivaroxaban 52 Diabetic Macular Edema 52 CALGB 52 RhuDex 52 NATRECOR R 52 CYPHER R stent 52 lopinavir r 52 CRLX# 52 unfractionated heparin UFH 52 Peginterferon 52 ACCOMPLISH 52 beclomethasone dipropionate 52 Aryplase 52 chronic ITP patients 52 docetaxel Taxotere R 52 trabedersen 52 tipranavir r 52 FOLPI 52 LATUDA 52 APEX AMI trial 52 insulin degludec 52 esomeprazole 52 Long Term Efficacy 52 direct thrombin inhibitor 52 febuxostat 52 reboxetine 52 COU AA 52 Adenoma Prevention 52 mGluR5 negative 52 everolimus eluting stent 52 boosted protease inhibitor 52 immunogenicity 52 rilonacept 52 mixed hyperlipidemia 52 CK # 52 liposomal formulation 52 CYPHER ® Stent 52 EMPHASIS HF trial 52 clinically meaningful 52 neurogenic orthostatic hypotension 52 INVEGA ® 52 plus dexamethasone 52 estramustine 52 μg kg 52 ximelagatran 52 longitudinal cohort study 52 PERSEUS 52 Phase III Pivotal 52 subcutaneous methylnaltrexone 52 doxorubicin docetaxel 52 IIa clinical 52 baminercept 52 ofatumumab 52 selective androgen receptor modulator 52 INCB# [003] 52 Phase III ALLEGRO 52 imetelstat 52 CR# vcMMAE 52 randomization 52 fistulizing Crohn disease 52 Phase Ib IIa 52 Pharmacokinetic 52 Stenting Trial CREST 52 TEMSO 52 DermaVir Patch 52 CALGB # [002] 52 RCTs 52 CA4P 52 IPX# 52 Tanespimycin 52 Phase IIb clinical trials 52 paclitaxel eluting stents 52 paclitaxel poliglumex 52 virologic 52 velafermin 52 TAXUS 52 lopinavir ritonavir 52 randomized discontinuation trial 52 EmbraceAC 52 triamcinolone 52 Board DSMB 52 Intervention Effectiveness CATIE 52 certolizumab 52 plus methotrexate 52 ZD# [001] 52 carcinogenicity study 52 dual antiplatelet therapy 52 Ozarelix 52 Locteron 52 PEG INTRON R 52 TOLAMBA 52 fosbretabulin 52 acute coronary syndromes ACS 52 GLYX 52 primary efficacy endpoints 52 Ranolazine 52 PRT# 52 PEGINTRON TM 52 HGS ETR1 52 romiplostim 52 bronchial thermoplasty 52 idraparinux 52 oral anticoagulant 52 retinal thickness 52 ganetespib 52 SNRI 52 arbaclofen 52 tezampanel 52 Phase IIb Trial 52 latrepirdine 52 guanfacine 52 metformin sulfonylurea 52 EDEMA4 52 IV bolus 52 LT NS#